VANCOUVER, British Columbia, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Willow Biosciences Inc. (TSX: WLLW, OTCQX: CANSF), based in Vancouver, Canada, focused on manufacturing pharmaceutical grade quality cannabinoids via synthetic biology, today announced that Trevor Peters, President and Chief Executive Officer, will present live at LifeSciencesInvestorForum.com on September 17th.
DATE: Thursday, September 17th
TIME: 2:30 PM ET
LINK: https://bit.ly/30GjErk
This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.
Learn more about the event at www.lifesciencesinvestorforum.com.
Recent Company Highlights
- In July of 2020, Willow announced it had commenced its 500-liter pilot for its first cannabinoid. The pilot was ahead of schedule based on success of science and interest from multi-national consumer packaged goods companies.
- Samples from Willow’s pilot program will be available in September 2020 and will make Willow the first to biosynthetically produce material amounts of cannabinoids.
- In June 2020, Willow announced that it will be adding four more cannabinoids to its portfolio, in addition to CBD – CBG, CBGV, CBDV, THCV.
- Willow expects to commercialize its first cannabinoid in the first half of 2021.
About Willow Biosciences Inc.
Willow is a Canadian biotechnology company based in Vancouver, Canada, that produces high purity, plant-derived compounds that provide building blocks for the global pharmaceutical, health and wellness, and consumer packaged goods industries. Willow's current focus is in the production of cannabinoids for the treatment for pain, anxiety, obesity, brain disorders, among other significant indications. Willow's science team has a proven track record of developing manufacturing technologies for high purity compounds in pain and cancer treatments. Willow's manufacturing process creates a consistent, scalable and sustainable product that allows for the discovery and development of new life changing drugs.
About Life Sciences Investor Forum
Life Sciences Investor Forum is the leading proprietary investor conference series that provides an interactive forum for Life Sciences companies to meet with and present directly to investors.
A real-time solution for investor engagement, Life Sciences Investor Forum is powered by Intrado Digital Media and specifically designed for more efficient investor access. Replicating the look and feel of on-site investor conferences, Life Sciences Investor Forum combines leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.
CONTACTS: Willow Biosciences Inc. Troy Talkkari, CFA Vice President, Corporate Development (403) 618-1117 t.talkkari@willowbio.com Life Sciences Investor Forum John M. Viglotti SVP Corporate Services, Investor Access (212) 220-2221 johnv@lifesciencesinvestorforum.com
